Pyritinol
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 2.5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C16H20N2O4S2 |
Molar mass | 368.473 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Pyritinol |
Articles |
---|
Most recent articles on Pyritinol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Pyritinol at Clinical Trials.gov Clinical Trials on Pyritinol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Pyritinol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Pyritinol Discussion groups on Pyritinol Directions to Hospitals Treating Pyritinol Risk calculators and risk factors for Pyritinol
|
Healthcare Provider Resources |
Causes & Risk Factors for Pyritinol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pyritinol also called pyridoxine disulfide or pyrithioxine (European drug names Encephabol, Encefabol, Cerbon 6) is a semi-natural water soluble analog of vitamin B6 (Pyridoxine HCl). It was produced in 1961 by Merck Laboratories by bonding 2 vitamin B6 compounds (pyridoxine) together with a disulfide bridge. Since the 1970s, it has been a prescription and OTC drug in several countries for cognitive disorders and learning disorders in children. Since the early 1990s it has been sold as a nootropic dietary supplement in the United States.
It is approved for "symptomatic treatment of chronically impaired brain function in dementia syndromes" and for "supportive treatment of sequelae of craniocerebral trauma" in various European countries, including Austria, Germany, France, Italy, Portugal, and Greece.
In France it is also approved for rheumatoid arthritis as a disease modifying drug, on the basis of the results of clinical trials.
It is not licensed for use in the United Kingdom, but in many countries it is available over the counter and is widely advertised on the internet as being for "memory disturbances." From the known sales data, it is estimated that more than 100 000 individuals in European Union countries have taken pyritinol in the past five years.
One small study, with 12 subjects given pyritinol, showed an improvement in performance on tests of reaction time, but not on memory tests.[1]
Some studies have found large doses of Pyritinol can help to reduce hangovers.[2]
Common dosages are 100-1,600 mg daily, taken in 1-3 doses during the day.
Adverse effects
Adverse effects include nausea, headache, and rarely allergic reaction.[citation needed] A 2004 survey of six case reports suggested a link between pyritinol and severe cholestatic hepatitis when on several drugs for certain diseases.[3]
Other rare side effects: acute pancreatitis[4] and photoallergic eruption.[5]
See also
References
- ↑ Hindmarch I, Coleston DM, Kerr JS (1990). "Psychopharmacological effects of pyritinol in normal volunteers". Neuropsychobiology. 24 (3): 159–64. doi:10.1159/000119478. PMID 2135070.
- ↑ Wiese JG, Shlipak MG, Browner WS (June 2000). "The alcohol hangover". Annals of Internal Medicine. 132 (11): 897–902. doi:10.7326/0003-4819-132-11-200006060-00008. PMID 10836917.
- ↑ Maria V, Albuquerque A, Loureiro A, Sousa A, Victorino R (March 2004). "Severe cholestatic hepatitis induced by pyritinol". BMJ (Clinical Research Ed.). 328 (7439): 572–4. doi:10.1136/bmj.328.7439.572. PMC 381054. PMID 15001508.
- ↑ Straumann A, Bauer M, Pichler WJ, Pirovino M (August 1998). "Acute pancreatitis due to pyritinol: an immune-mediated phenomenon". Gastroenterology. 115 (2): 452–4. doi:10.1016/S0016-5085(98)70212-4. PMID 9679051.
- ↑ Tanaka M, Niizeki H, Shimizu S, Miyakawa S (October 1996). "Photoallergic drug eruption due to pyridoxine hydrochloride". The Journal of Dermatology. 23 (10): 708–9. PMID 8973037.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- All articles with unsourced statements
- Articles with unsourced statements from November 2008
- Articles with invalid date parameter in template
- Drug
- Antioxidants
- Nootropics
- Organic disulfides
- Pyridines
- Phenols
- Alcohols